Voxel touts FDA-cleared holography

Article

Look for 3-D holography developer Voxel to emphasize the new regulatorystatus of its technology. The Laguna Hills, CA, firm will enjoyits first RSNA meeting with Food and Drug Administration clearancefor its products (SCAN 10/11/95). Voxel uses a

Look for 3-D holography developer Voxel to emphasize the new regulatorystatus of its technology. The Laguna Hills, CA, firm will enjoyits first RSNA meeting with Food and Drug Administration clearancefor its products (SCAN 10/11/95).

Voxel uses a proprietary camera to create VoxGrams, or holographicimages, that seem to reach out into space when they are viewed.Voxel believes the enhanced perspective will help clinicians whenviewing images.

Voxel will show ongoing clinical work using VoxGrams in neurologicaland breast imaging. The company plans to begin beta-site installationsof the system next year.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.